Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acid synthesis. Very high doses of biotin may be efficacious in multiple sclerosis (MS) by promoting myelin repair through activation of acetyl-CoA carboxylase, and by enhancing energy production in demyelinated neurons through activation of the tricarboxylic acid (Kreb's) cycle. Biotin is intended for use as an add-on therapy for permanent disability related to MS relapses, and is administered orally at 100mg three times daily for up to 24 months.
MS is a chronic immune-mediated condition of the central nervous system characterised by demyelination and axonal degeneration. Resultant damage leads to a wide spectrum of symptoms and signs, potentially including difficulties with weakness, sensory disturbance, balance and vision.
The prevalence of MS in England is approximately 0.16%, equivalent to approximately 85,600 affected people in England. Approximately 35.5% of patients have relapsing-remitting disease, equating to around 30,388 people in England. After two decades, more than half of patients who suffer from RRMS enter a secondary progressive phase.
Biotin is currently undergoing a phase III clinical trial assessing its effect on best corrected visual acuity compared with placebo. This trial is expected to complete by January 2016. Indexing Status Subject indexing assigned by CRD MeSH Adjuvants, Immunologic; Biotin; Humans; Immunologic Factors; Multiple Sclerosis; Psychotherapy, Multiple; Recurrence Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000337 Date abstract record published 03/03/2016 |